Drug switching and virologic-based endpoints in trials of antiretroviral drugs for HIV infection

This publication has 18 references indexed in Scilit:

• Explanatory and pragmatic attitudes in therapeutical trials
  Published by Elsevier ,2004
• Definition of loss of virological response in trials of antiretroviral drugs
  AIDS, 2003
• Lopinavir–Ritonavir versus Nelfinavir for the Initial Treatment of HIV Infection
  New England Journal of Medicine, 2002
• Raised viral load in patients with viral suppression on highly active antiretroviral therapy: transient increase or treatment failure?
  AIDS, 2002
• Abacavir-Lamivudine-Zidovudine vs Indinavir-Lamivudine-Zidovudine in Antiretroviral-Naive HIV-Infected AdultsA Randomized Equivalence Trial
  JAMA, 2001
• Human Immunodeficiency Virus Type 1 RNA Level and CD4 Count as Prognostic Markers and Surrogate End Points: A Meta-Analysis
  AIDS Research and Human Retroviruses, 2000
• Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients
  AIDS, 2000
• Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in Adults
  New England Journal of Medicine, 1999
• A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or Less
  New England Journal of Medicine, 1997
• A Trial Comparing Nucleoside Monotherapy with Combination Therapy in HIV-Infected Adults with CD4 Cell Counts from 200 to 500 per Cubic Millimeter
  New England Journal of Medicine, 1996